Holen Sie sich die Stockscreener-App
469.68
2.99%
-14.47
Handel nachbörslich:
471.00
1.32
+0.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$484.15
Offen:
$481.505
24-Stunden-Volumen:
1.74M
Relative Volume:
1.30
Marktkapitalisierung:
$119.17B
Einnahmen:
$11.74B
Nettoeinkommen (Verlust:
$3.68B
KGV:
33.10
EPS:
14.1888
Netto-Cashflow:
$3.34B
1W Leistung:
+3.60%
1M Leistung:
+6.25%
6M Leistung:
+0.71%
1J Leistung:
+13.97%
1-Tages-Spanne:
$465.28
$485.69
1-Wochen-Bereich:
$443.12
$487.52
52-Wochen-Spanne:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Mkt Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Hochstufung | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Wagner, Vertex Pharmaceuticals evp, sells $4.39m in VRTX stock By Investing.com - Investing.com UK
Vertex Advances Suzetrigine Phase 3 Trial in Diabetic Nerve Pain, Signaling a Broader Growth Story - TipRanks
RBC Raises Price Target on Vertex Pharmaceuticals to $455 From $415, Keeps Sector Perform Rating - MarketScreener
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewswire Inc.
Vertex Pharmaceuticals: The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade) - Seeking Alpha
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts - Benzinga
‘We were sitting with our calculator saying “we can afford that!”’ Joy for families as cystic fibrosis drug prices fall within reach - The Guardian
Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies - The Globe and Mail
UBS Lowers Price Target for Vertex Pharmaceuticals (VRTX) to $53 - GuruFocus
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why - Finviz
Wolfe Research Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Wolfe Research Upgrades Vertex Pharmaceuticals (VRTX) to Outperf - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Outperform at Wolfe Research - MarketBeat
Wolfe Research Upgrades Vertex Pharmaceuticals to Outperform From Peer Perform, Price Target is $548 - MarketScreener
Robeco Institutional Asset Management B.V. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Advisory Resource Group Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings - Benzinga
5 Clinical Readouts to Watch in H1 2026 - BioSpace
Vertex Pharmaceuticals Incorporated $VRTX Position Increased by Asset Management One Co. Ltd. - MarketBeat
Aug Retail: Will Vertex Pharmaceuticals Incorporated VX1 stock test record highs in 2025Trade Volume Report & Verified Chart Pattern Signals - moha.gov.vn
Generali Asset Management SPA SGR Acquires 6,942 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Coastline Trust Co Sells 3,145 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Best Biotech Stocks To Follow NowJanuary 1st - MarketBeat
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
The Best Stocks to Invest $1,000 in to Start the New Year Off Right - Finviz
When Phase 3 Data Drops, What Determines A Sustained Rally Vs. A Fading Initial Pop - Benzinga
25,734 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Generate Investment Management Ltd - MarketBeat
Ethic Inc. Has $5.47 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - sharewise.com
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock - Nasdaq
2 Growth Stocks to Buy For 2026 and Beyond - Finviz
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink - Yahoo Finance
Orna Therapeutics collaborates with Vertex Pharmaceuticals to develop approaches for sickle cell disease - MSN
Vertex Pharmaceuticals (VRTX) Target Price Raised to $525 by Lee - GuruFocus
Leerink Partners Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $525.00 - MarketBeat
Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook? - Insider Monkey
Vertex Pharma’s Cystic Fibrosis Franchise: How Trikafta Powers the Pipeline — and the Stock - AD HOC NEWS
Biotech Stocks To Keep An Eye OnDecember 25th - MarketBeat
Burney Co. Reduces Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock: Biotech momentum meets Wall Street optimism - AD HOC NEWS
Forget Moderna Stock, This is a Much Better Buy - Finviz
Vertex Pharmaceuticals Earnings Notes - Trefis
Greenwood Capital Associates LLC Acquires 2,514 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Pacer Advisors Inc. Acquires 26,543 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Market Review: How analysts rate Vertex Pharmaceuticals Incorporated stock todayJuly 2025 Fed Impact & Long-Term Safe Investment Plans - moha.gov.vn
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq? - MSN
Exchange Traded Concepts LLC Purchases 7,565 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):